relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: a cohort study from han chinese

background: this study was designed to investigate the eff ect of clopidogrel-related gene polymorphisms on platelet reactivity and clinical outcome in chinese han patients. materials and methods: th ree hundred and thirty-six percutaneous coronary intervention - treated patients were recruited and followed for 1 year. blood samples were collected from all patients for dna genotyping. th e platelet reactivity unit was measured by the verifynow technique. th e cyp2c19*2, cyp2c19*3, cyp2c19*17,atp-binding cassette subfamily b member 1, itgb3, cyp2c9*3, cyp2b6*9, and p2y12 alleles were assessed. results: th e clinical endpoints were related to previous heart disease history (11.90% vs. 28.57%, p = 0.017), stroke (12.24% vs. 16.67%, p = 0.039), and diabetes (27.55% vs. 52.38%, p = 0.047). high on-treatment platelet reactivity (htpr) was frequent in advanced age (p = 0.019), male gender (p = 0.016), hypertension (p = 0.033), and chronic renal failure (p = 0.040). th ere were more endpoints in the cyp2c19*2 and p2y12 mutant carriers (76.19% vs. 43.20%, p < 0.001; 50.00% vs. 35.71%, p = 0.001, respectively), whereas fewer in the cyp2c19*17 mutant carriers (11.90% vs. 56.46%, p = 0.001). cyp2c19*2 and p2y12 polymorphism manifested htpr (194.25 ± 45.91 vs.151.38 ± 58.14, p < 0.001; 180.33 ± 67.25 vs. 161.89 ± 56.49, p = 0.008, respectively), whereas cyp2c19*17 mutant improved platelet reactivity (97.17 ± 45.38 vs. 169.08 ± 57.15, p = 0.003). however, there were no further cardiovascular deaths in endpoint patients.conclusion: in han chinese people of mainland china, clopidogrel-related gene polymorphisms are related to variable platelet reactivity after clopidogrel maintenance dosing, which infl uences major adverse cardiovascular events, without an eff ect on cardiac death.